At the same time, the findings for clinical studies were more mixed, and long-term trials showed the possibility of a lower dementia risk with these drugs, but shorter trials did not show consistent cognitive improvements
This creates both benefits and possible complications
However, the long-term effects on a patients health beyond the trial timelines and on the costs to the healthcare system are still uncertain
Cancers (Basel) 9 , 90, (2017)
It is a close structural analogue of the naturallyoccurring GHK-Cu (Copper Tripeptide1), differing only in a single Nterminal residue: alanine in place of glycine (one methyl group)
Harley KG, Rauch SA, Chevrier J, Kogut K, Parra KL, Trujillo C, Lustig RH , Greenspan LC, Sjdin A, Bradman A, Eskenazi B